I think the key advance in using AI and also digital platforms and specific phenotyping and genotyping is really not only relevant, but it’s the next hot topic in neurodegenerative aspects. So there are many uses with AI and in particular with digital tools. We discuss a lot about how AI could bring scalable tools for the screening procedure, but also to be able to identify the right targets and to be able also to design better clinical trials, in particular with a reduction of the side effects of the treatment to be able to have more powerful clinical trials...
I think the key advance in using AI and also digital platforms and specific phenotyping and genotyping is really not only relevant, but it’s the next hot topic in neurodegenerative aspects. So there are many uses with AI and in particular with digital tools. We discuss a lot about how AI could bring scalable tools for the screening procedure, but also to be able to identify the right targets and to be able also to design better clinical trials, in particular with a reduction of the side effects of the treatment to be able to have more powerful clinical trials. And then there are a lot of new aspects in AI and digital tools that are moving not only in memory clinics, but also at a GP level and at a population level. So it was really to discuss what could be the perspective, what is done already, what could be the perspective of using this type of tools in our population to be more efficient and be more scalable in terms of screening and in terms of the next steps of the preventive strategy.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
